Navigation Links
Pagoclone in Medical News

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as mus...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, ...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development...

Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About Orion Corporation ( http://www.orion.fi ) Orion is a European pharmaceutical and diagnostics company which emphasises the de...

Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals To Present at RBC Capital Markets Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

With an aim to cure stuttering

...ng to the company. However, even larger trials were needed. According to New York Times, larger trials could take 2-3 years but if they succeed, pagoclone would become the first medicine for treating the problem. Research is concentrating on the idea that stammering is a neurological problem, which...
Pagoclone in Medical Technology

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously anno...

Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting

Open-label Extension of Phase II Study Demonstrates Significant Additional Improvement for Patients on Pagoclone LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that results from the Company's Phase II EXPRESS trial for pagoclone in persisten...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Secur...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal microbicide to prevent the s...

Indevus Pharmaceuticals Provides Update on PRO 2000 Program

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. PRO 2000 PRO 2000 (naphthalene sulfonate polymer) is a topical vaginal microbicide under development to prevent the sexual transmi...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Announces Submission of New Drug Application

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Reports Positive Data From Phase III NEBIDO Trial

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...
Pagoclone in Biological Technology

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L. DeCarlo Sr. Directo...

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

...late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million ...ent with Teva for the development and marketing of pagoclone for the treatment of stuttering. In the first cal... Allergan -- Licensing of Worldwide Rights for pagoclone to Teva Corporate -- Issuance of U.S. Pa...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About the Jericho Road Episcopal Housing Initiative The Jericho Road Episcopal Housing Initiative creates quality homes for famili...

Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Announces Allergan as New Partner for SANCTURA Brand

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA(R) XR belong to a class of anticholinergic compounds known as muscarinic rec...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...
Other Tags
(Date:5/1/2015)... 02, 2015 IDLife LLC, a health ... to announce the addition of its newest partner and ... life long athlete, growing up in gymnastics and competitive ... by becoming a personal trainer and helping others achieve ... of several TV shows highlighting her stunning physique and ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... Royal River Natural Foods, a locally-owned independent natural ... study that found two natural nutrients, glucosamine and chondroitin, ... as well as standard drug treatment after six months ... The report is part of the May 2015 issue ... Royal River Natural Foods publishes for free each month ...
(Date:5/1/2015)... 2015 TROY Healthcare Solutions is proud ... User Group (RUG) Conference in Atlanta, GA from May ... Group Conference provides a forum for client-to-client presentations, continuing ... aspects of electronic medical record operations, as well as ... , In addition to sponsoring the event, TROY Healthcare ...
(Date:5/1/2015)... May 01, 2015 Hope For The ... of Hope For The Warriors® and military families. All ... support Hope For The Warriors®, a national nonprofit dedicated ... unit, and restoring hope for our service members and ... All American Ford collected and matched small autograph fee ...
Breaking Medicine News(10 mins):Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
Other Contents